Literature DB >> 26076396

Clinical and Molecular Characteristics of Non-Transfusion-Dependent Thalassemia in Kuwait.

Adekunle D Adekile1, Asma F Azab, Sondus I Al-Sharida, Bahia A Al-Nafisi, Nagihan Akbulut, Rajaa A Marouf, Nada Y Mustafa.   

Abstract

Although not regularly transfused, patients with non-transfusion-dependent thalassemia (NTDT) are prone to iron overload and its complications. Their molecular, phenotypical and laboratory characteristics vary in different populations and there is a need to document local prevailing patterns. We have reviewed the records of our patients with NTDT in Kuwait and documented their clinical and molecular characteristics in addition to iron status [serum ferritin and liver magnetic resonance imaging (MRI) T2*], management and complications. There were 41 patients, made up of 20 with β-thalassemia intermedia (β-TI), 18 with Hb H (β4) disease and three with Hb E (HBB: c.79G > A)-β-thalassemia (Hb E-β-thal); their ages ranged from 3 to 36 years (mean 12.5 ± 7.7). While 18 (43.9%) had been transfused at least once, only three (7.3%) had been transfused on multiple occasions. Three patients had serum ferritin >500 ng/mL; while four of 38 had mild or moderate liver iron overload. Seven (35.0%) of the β-TI patients were managed with hydroxyurea (HU) with good response. Other complications included five patients with gallstones and one each of hypothyroidism and moyamoya. The most common mutations among the β-TI patients were IVS-II-1 (G > A) and IVS-I-6 (T > C), while among the Hb H patients, the Saudi α2-globin gene polyadenylation (polyA) (AATAAA > AATAAG) mutation was responsible for all cases either as homozygotes (61.1%) or compound heterozygotes with the α-thal-2 (-α(3.7)) allele (33.3%). Although the pattern of NTDT in Kuwaiti patients is generally mild, there is a need to follow them to adulthood as the complications are cumulative and more prevalent in this group.

Entities:  

Keywords:  Hb E-β-thalassemia (Hb E-β-thal); Hb H (β4); Kuwait; non-transfusion-dependent thalassemia (NTDT); β-Thalassemia intermedia (β-TI)

Mesh:

Substances:

Year:  2015        PMID: 26076396     DOI: 10.3109/03630269.2015.1053489

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  4 in total

1.  HLA Haplotype Frequencies and Genetic Profiles of the Kuwaiti Population.

Authors:  Reem Ameen; Salem H Al Shemmari; Steven G E Marsh
Journal:  Med Princ Pract       Date:  2019-03-15       Impact factor: 1.927

Review 2.  Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  Drug Des Devel Ther       Date:  2016-01-29       Impact factor: 4.162

3.  Xmn1-158 γGVariant in B-Thalassemia Intermediate Patients in South-East of Iran.

Authors:  Ebrahim Miri-Moghaddam; Sara Bahrami; Majid Naderi; Ali Bazi; Morteza Karimipoor
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2017-04-01

4.  Genotype-phenotype correlation in patients with deletional and nondeletional mutations of Hb H disease in Southwest of Iran.

Authors:  Mohammad Hamid; Bijan Keikhaei; Hamid Galehdari; Alihossein Saberi; Alireza Sedaghat; Gholamreza Shariati; Marziye Mohammadi-Anaei
Journal:  Sci Rep       Date:  2022-03-22       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.